Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,990.57% | 14,889.38% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,990.57% | 14,889.38% | -- | -- | -- |
| Cost of Revenue | 18.61% | 53.89% | 47.82% | 99.61% | 316.95% |
| Gross Profit | 158.53% | 154.76% | 51.23% | -70.18% | -293.50% |
| SG&A Expenses | -2.82% | 10.91% | 15.81% | -3.47% | 6.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.29% | 11.41% | 9.37% | 2.14% | 9.71% |
| Operating Income | 110.73% | 98.52% | 43.40% | 8.48% | -5.36% |
| Income Before Tax | 121.88% | 107.02% | 48.06% | 10.20% | -3.84% |
| Income Tax Expenses | 781.16% | 685.99% | 660.36% | 6.67% | 154.21% |
| Earnings from Continuing Operations | 118.53% | 104.55% | 46.29% | 10.15% | -4.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 118.53% | 104.55% | 46.29% | 10.15% | -4.07% |
| EBIT | 110.73% | 98.52% | 43.40% | 8.48% | -5.36% |
| EBITDA | 117.68% | 104.48% | 46.76% | 9.03% | -5.19% |
| EPS Basic | 113.11% | 100.71% | 59.01% | 31.92% | 12.96% |
| Normalized Basic EPS | 115.44% | 102.30% | 60.09% | 31.88% | 13.06% |
| EPS Diluted | 113.03% | 100.50% | 58.84% | 31.75% | 12.78% |
| Normalized Diluted EPS | 115.19% | 102.08% | 60.09% | 31.88% | 13.06% |
| Average Basic Shares Outstanding | 37.93% | 46.77% | 43.79% | 36.88% | 22.49% |
| Average Diluted Shares Outstanding | 38.27% | 47.15% | 43.79% | 36.88% | 22.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |